Clinical Trials Logo

Liver Fibrosis clinical trials

View clinical trials related to Liver Fibrosis.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 2

NCT ID: NCT01133184 Not yet recruiting - Liver Fibrosis Clinical Trials

Improved Prevention of Perinatal Hepatitis B Transmission

Start date: September 2010
Phase: Phase 4
Study type: Interventional

Impaired activity of Natural Killer (NK) cells has been proposed as a mechanism contributing to viral persistence in Hepatitis C Virus (HCV) infection. NK cells display anti-fibrotic activities by killing activated hepatic stellate cells (HSCs) that have lost the self-recognition marker; Major Histocompatibility (MHC) class I. Determining the down-expressed genes on NK cells necessary for their anti-fibrotic activity was never studied previously. This will allow us to study their role fully in phagocytosis process as well as their interaction of HSCs and therefore manipulating these genes using molecular techniques. Exploring the cellular functions of these genes will highlight their involvement in the progression of liver fibrosis and could be used as a therapeutic tool for preventing the disease.